CD274 and lymphoma: Despite these negative findings involving combination with PD-L1 antibodies, the CTX140 1q6d treatment regimen may be compatible for combining with other immunotherapies; for example, in preclinical models of lymphoma, CTX was found to successfully synergize with blockade of the “don’t eat me” signal CD47, which resulted in enhanced dendritic cell antigen presentation and T cell-mediated clearance of A20 lymphoma cells46.